Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· No medical condition. Β· Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs β€” 642 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website β†— All projects Drug pipeline News & analysis
Intelligence Β· Clinical Programs

Anaxis Pharma projects

642 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

642 programs

Clinical programs

Page 7 of 14

  1. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  2. HDP-101

    Lacuna Pharma Pty Ltd

    Relapsed or refractory Multiple Myeloma (r/r MM)

    phase 2 small molecule active

    1 trial

  3. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Lacuna Pharma Pty Ltd

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  4. ICP-CL-00609

    Lacuna Pharma Pty Ltd

    Prurigo Nodularis

    phase 2 small molecule active

    1 trial

  5. ID-078A205

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  6. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  7. IMB101-010

    Lacuna Pharma Pty Ltd

    Non-obstructive hypertrophic cardiomyopathy

    phase 2 small molecule active

    1 trial

  8. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  9. IPH5201-201

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  10. IPH6501

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  11. IRINOTECAN, lurbinectedin

    Lacuna Pharma Pty Ltd

    Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  12. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  13. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

  14. KL264-01

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  15. KT-US-982-5968

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial

  16. KTE-C19-102

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  17. LGON-CT-002

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  18. Lacutamab

    Lacuna Pharma Pty Ltd

    Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory SΓ©zary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

    phase 2 small molecule active

    1 trial

  19. MED-004-EC-25

    Lacuna Pharma Pty Ltd

    facial melasma

    phase 2 other active

    1 trial

  20. METRONIDAZOLE for Pouchitis

    Lacuna Pharma Pty Ltd

    Pouchitis

    phase 2 small molecule active

    1 trial

  21. MITAPIVAT

    Lacuna Pharma Pty Ltd

    Sickle Cell Disease (SCD) and Nephropathy

    phase 2 small molecule active

    1 trial

  22. Meropenem-Vaborbactam

    Lacuna Pharma Pty Ltd

    Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)

    phase 2 small molecule active

    1 trial

  23. NMD670, Placebo

    Lacuna Pharma Pty Ltd

    Charcot-Marie-Tooth Disease Type 1 and Type 2

    phase 2 small molecule active

    1 trial

  24. NMD670-02-0001

    Lacuna Pharma Pty Ltd

    Type 3 spinal muscular atrophy

    phase 2 small molecule active

    1 trial

  25. NMD670-02-0002

    Lacuna Pharma Pty Ltd

    Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  26. NOE-TSC-201

    Lacuna Pharma Pty Ltd

    Tuberous Sclerosis Complex

    phase 2 small molecule active

    1 trial

  27. NOE-TTS-201

    Lacuna Pharma Pty Ltd

    Tourette Syndrome

    phase 2 small molecule active

    1 trial

  28. NS229-P2-01

    Lacuna Pharma Pty Ltd

    Eosinophilic granulomatosis with polyangiitis (EGPA)

    phase 2 small molecule active

    1 trial

  29. NX210c for Amyotrophic Lateral Sclerosis (ALS)

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  30. Neflamapimod

    Lacuna Pharma Pty Ltd

    Dementia with Lewy Bodies (DLB)

    phase 2 small molecule active

    1 trial

  31. OCTREOTIDE ACETATE, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Carcinoid Syndrome

    phase 2 small molecule active

    1 trial

  32. OMTX705-004

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  33. OMTX705-005

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. ONO-4578-10

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  35. Ocaliva 5 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Primary biliary cholangitis

    phase 2 small molecule active

    1 trial

  36. P-SP420-THAL-01

    Lacuna Pharma Pty Ltd

    transfusion-dependent Ξ±- or Ξ²-thalassemia or low-risk myelodysplastic syndromes

    phase 2 other active

    1 trial

  37. PAUF-I

    Lacuna Pharma Pty Ltd

    Advanced and/or metastatic pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  38. PDC-LUNG-101

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  39. PEMBROLIZUMAB, PM54

    Lacuna Pharma Pty Ltd

    Advanced malignancies

    phase 2 small molecule active

    1 trial

  40. PM14, IRINOTECAN

    Lacuna Pharma Pty Ltd

    Patients with Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  41. PM14-A-001-17

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 2 other active

    1 trial

  42. PRO RCT GRAM 2022

    Lacuna Pharma Pty Ltd

    allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial

  43. PRO-RCT-GRAM-2025-01

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial

  44. PSt012021

    Lacuna Pharma Pty Ltd

    Myopia progression in children

    phase 2 small molecule active

    1 trial

  45. PVX 2024-01

    Lacuna Pharma Pty Ltd

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  46. Paltusotine tablets, Paltusotine tablets

    Lacuna Pharma Pty Ltd

    Acromegaly

    phase 2 small molecule active

    1 trial

  47. Pariglasgene brecaparvovec

    Lacuna Pharma Pty Ltd

    Glycogen storage disease type Ia

    phase 2 small molecule active

    1 trial

  48. Phase 1/2A Study of OTP-01 for advanced solid tumors

    Lacuna Pharma Pty Ltd

    advanced solid tumors

    phase 2 other active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.